Wanbury’s (WL) Patalganga site has completed MFDS (Ministry of Food and Drug Safety - Korea FDA) Regulatory Inspection successfully. Two inspectors inspected facility for three days i.e. from April 07 2026 to April 09, 2026. Inspection completed with no observation (Zero Observation) confirming cGMP compliance per international rules.  

MFDS is part of PIC (Pharmaceutical inspection co-operation scheme). Company is strengthening  infrastructure by adding new state of the art manufacturing block at Andhra Pradesh site for new  APIs which under validation and commercialisation. 

Both the API manufacturing sites are USFDA approved i.e. Patalganga and Tanuku of WL are continued to be compliant as per cGMP Rules and Regulations with Zero Observation. Patalganga plant received zero observation from USFDA earlier. Thereafter, Tanuku plant received Zero Observation from Anvisa (Brazil FDA).  Now again, Patalganga plant got Korea FDA Approval with Zero Observation.

Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.